Table 3.
Univariate and multivariate survival analyses of patients with appendiceal goblet cell carcinomatosis after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
| Characteristic | Univariate analysis
|
Multivariate analysis
|
||
|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | |
| Age, 5-y intervals | 1.0 (0.8–1.3) | 0.88 | ||
| Sex | 0.5 (0.2–1.4) | 0.17 | ||
| Race | 0.3 (0.0–2.6) | 0.26 | ||
| Body mass index | 0.6 (0.4–1.1) | 0.12 | ||
| ECOG performance status | 34.6 (0.9–1410.6) | 0.06 | 1.7 (0.7–3.9) | 0.21 |
| Preoperative albumin | 0.1 (0.0–5.0) | 0.28 | ||
| Preoperative chemotherapy | 2.5 (0.7–9.0) | 0.15 | ||
| Postoperative chemotherapy | 1.9 (0.2–17.6) | 0.56 | ||
| HIPEC agent (oxaliplatin versus mitomycin C) | 1.4 (0.5–4.5) | 0.54 | ||
| No. of organs resected | 3.5 (0.5–23.5) | 0.20 | ||
| Peritoneal carcinomatosis index | 0.1 (0.0–6.4) | 0.32 | ||
| Positive lymph nodes | 13.7 (1.8–107.9) | 0.01 | 10.8 (1.3–88.8) | 0.02 |
| Incomplete resection (versus complete resection) | 1.5 (0.5–4.2) | 0.48 | ||
| Length of operation | 0.8 (0.3–2.3) | 0.66 | ||
CI = confidence interval; HIPEC = hyperthermic intraperitoneal chemotherapy; OR = odds ratio.